Viral Vector Formulation, Final Filtration and Filling
Formulation, final filtration, and filling are the last steps in viral vector production. A rational formulation design developed by optimizing solution conditions and high-quality excipients can significantly increase viral vector stability and shelf-life. Our wide range of high-quality buffers, salts and stabilizers, low in bioburden and endotoxins, are specifically developed for high-risk applications and can ensure successful downstream processing and formulation of your final gene therapy product.
Designing a successful single-use sterile filtration system should focus on maximizing the recovery of these high-value therapies and consider different filter options, process requirements, sampling needs, and if pre-use post-sterilization integrity testing (PUPSIT) will be performed.
Our Mobius® single-use assemblies offer you flexibility and our specialists can help you design a custom assembly from our broad portfolio of filters and single-use components. These systems are scalable and can be easily replicated to meet your evolving needs.
Supported by our Emprove® program, our excipients, filters and single-use components have extensive documentation, minimizing regulatory and quality-associated risks in your manufacturing. All this simplifies the complexity of your supplier qualification and speeds up processes, thus reducing the total cost of ownership.
- A broad excipient portfolio, manufactured according to the IPES PQG GMP guidelines
- Sterilizing-grade filters for viral vector purification
- Mobius® single-use assemblies for viral vector purification
- Validation services to confirm your single-use filtration system is suitable for processing
Related Technical Resources
- Brochure: Your Fast Track Through Regulatory Challenges – The Emprove® Program
Download our Emprove® Program brochure to learn more about how to improve your regulatory processes.
- White Paper: Identifying Appropriate-Quality Raw Materials in an Evolving Regulatory Environment
This white paper explains the challenges and keys to success in pharmaceutical manufacturing processes and raw material supply chains when it comes to sourcing raw materials in a continually evolving regulatory environment.
- Brochure: Pharma Raw and Starting Materials - Satisfy Your Regulatory Requirements
Confidently speed your way through the regulatory maze and fast track your new drug to market.
- Brochure: Emprove® Filters and Single-Use Components
Enabling a more robust risk assessment.
Workflow
Viral Vector Upstream Processing
Making the right upstream process decisions not only impacts viral vector titer, but downstream processes, timelines, and regulatory acceptance
Viral Vector Downstream Processing
Efficient virus purification processes can improve yield, decrease time to patient, and lower manufacturing costs
Viral Vector Characterization and Biosafety Testing
Critical biosafety testing and characterization of viral vector products can help to fully analyze key quality attributes: identity, potency, safety, and stability
Viral Vector Contract Development and Manufacturing
CDMO partnerships play a critical role in advancing clinical pipelines and achieving successful commercialization
Related Products
Millipak® Final Fill capsules are designed for reliable sterile filtration of small volume, high value solutions.
Durapore® sterilizing-grade 0.22 µm hydrophilic polyvinylidene fluoride (PVDF) membranes are low protein binding and provide sterility assurance, high flow rates and throughputs.
To continue reading please sign in or create an account.
Don't Have An Account?